Lumera Signs Agreement with Institute for Systems Biology to Address Cancer Detection
The revised collaboration agreement will focus on detection methods for an array of diagnostic biomarkers aimed at various types of cancer.
This announcement extends an agreement between Lumera and ISB announced in February of 2005. ISB was the first academic institution to test Lumera’s ProteomicProcessor™.
"We have been particularly pleased with the flexibility and functionality of Lumera’s ProteomicProcessor™ instrument and their NanoCapture™ chips," said Dr. Leroy Hood, president and co-founder of ISB and a world renowned visionary in the field of molecular immunology, biotechnology and genomics.
"We look forward to an expanded relationship with Lumera and continuing to utilize this technology on our quest to usher in a new era of predictive, preventive, and personalized medicine."
Since February of 2005, Harvard Medical School and Harvard Institute of Proteomics, Baylor University and the Medical University of South Carolina have joined ISB in beta testing Lumera’s ProteomicProcessor™.
The instrument has evolved as a result of their feedback and the company expects to launch a refined commercial ProteomicProcessor™ product in January at the CHI PepTalk conference, an internationally recognized forum for protein arrays and detection technologies.
"We have spent time gathering the necessary feedback and seals of approval from renowned experts and research institutions as it relates to our ProteomicProcessor™ and NanoCapture™ microarrays," said Lumera CEO Tom Mino.
"It has been a deliberate and necessary process in developing and readying our proprietary product line for the market. We are now nearing the commercial launching pad."
"The ISB application of discovering cancer biomarkers in serum is exciting and provides significant potential for future applications," said Dr. Tim Londergan, director of Lumera’s Bioscience Business Unit.
"Utilizing partners such as ISB to develop new applications enables us to build a pipeline of high value products, while allowing our internal product development to remain focused on near term market demands."
The initial commercial launch of the ProteomicProcessor™ and NanoCapture™ microarrays will be focused on the therapeutic antibody screening market.